Michelle Poon
YOU?
Author Swipe
View article: Patient-reported outcomes in relapsed/refractory diffuse large B-cell lymphoma with odronextamab monotherapy
Patient-reported outcomes in relapsed/refractory diffuse large B-cell lymphoma with odronextamab monotherapy Open
In the ELM-2 study (NCT03888105) of patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) (n = 141), odronextamab 160 mg weekly (after step-up dosing) significantly improved Functional Assessment of Cancer Therapy-Lym…
View article: Outcomes of Autologous Stem Cell Transplant in Primary and Secondary Central Nervous System Lymphoma - a Multi Center Experience in Singapore
Outcomes of Autologous Stem Cell Transplant in Primary and Secondary Central Nervous System Lymphoma - a Multi Center Experience in Singapore Open
Introduction Central Nervous System Lymphoma, either primary (PCNSL) or secondary (SCNSL), is a rare and aggressive extranodal lymphoma with poor outcomes due to poor blood-brain barrier penetrance, treatment associated neurotoxicity, and …
View article: Outcomes of Elderly Patients with DLBCL and Utility of Geriatric Assessment Tools to Predict Chemotoxicity
Outcomes of Elderly Patients with DLBCL and Utility of Geriatric Assessment Tools to Predict Chemotoxicity Open
Background: Treatment strategies in elderly DLBCL is challenging due to associated comorbidities. Conventional performance status indices do not account for physiologic effects of aging and may have limited predictive value. Geriatric asse…
View article: Survival Outcomes, Efficacy and Tolerability of a Pediatric-Inspired Regimen (MASPORE) for Philadelphia-Negative Acute Lymphoblastic Leukemia in Young Adults at a Tertiary Hospital in Singapore
Survival Outcomes, Efficacy and Tolerability of a Pediatric-Inspired Regimen (MASPORE) for Philadelphia-Negative Acute Lymphoblastic Leukemia in Young Adults at a Tertiary Hospital in Singapore Open
Introduction: Recent evidence has emerged to support the use of pediatric-inspired regimen as a standard of care in Adolescents and Young Adults (AYA) patients diagnosed with Philadelphia-negative acute lymphoblastic leukemia (Ph- ALL). Th…
View article: P1083: ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA GRADE 1–3A: RESULTS FROM A PRESPECIFIED ANALYSIS OF THE PIVOTAL PHASE 2 STUDY ELM-2
P1083: ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA GRADE 1–3A: RESULTS FROM A PRESPECIFIED ANALYSIS OF THE PIVOTAL PHASE 2 STUDY ELM-2 Open
Topic: 18. Indolent and mantle-cell non-Hodgkin lymphoma - Clinical Background: Odronextamab is a CD20×CD3 bispecific antibody (Ab). In the Phase 1 ELM-1 study (NCT02290951), odronextamab demonstrated potent antitumor activity and a genera…
View article: P1118: LONGER FOLLOW-UP FROM THE PIVOTAL EPCORE NHL-1 TRIAL REAFFIRMS SUBCUTANEOUS EPCORITAMAB INDUCES DEEP, DURABLE COMPLETE REMISSIONS IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA
P1118: LONGER FOLLOW-UP FROM THE PIVOTAL EPCORE NHL-1 TRIAL REAFFIRMS SUBCUTANEOUS EPCORITAMAB INDUCES DEEP, DURABLE COMPLETE REMISSIONS IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA Open
Topic: 19. Aggressive Non-Hodgkin lymphoma - Clinical Background: Outcomes are poor for patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL). Effective treatments that drive deep, durable responses and long-term benefit are…
View article: P1115: ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: RESULTS FROM A PRESPECIFIED ANALYSIS OF THE PIVOTAL PHASE 2 STUDY ELM-2
P1115: ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: RESULTS FROM A PRESPECIFIED ANALYSIS OF THE PIVOTAL PHASE 2 STUDY ELM-2 Open
Topic: 19. Aggressive Non-Hodgkin lymphoma - Clinical Background: Odronextamab is a CD20×CD3 bispecific antibody (Ab). In the Phase 1 ELM-1 study (NCT02290951), odronextamab demonstrated encouraging activity and a generally manageable safe…
View article: Clinical features and prognostic outcomes of angioimmunoblastic T cell lymphoma in an Asian multicenter study
Clinical features and prognostic outcomes of angioimmunoblastic T cell lymphoma in an Asian multicenter study Open
In our Asian multicenter retrospective study, we investigated the clinical prognostic factors affecting the outcomes of AITL patients and identified a novel prognostic index relevant in the Asian context. In our 174-patient cohort, the med…
View article: DURABLE LONG‐TERM REMISSION IN HIGH‐RISK RELAPSE REFRACTORY LYMPHOMA—20 YEARS’ EXPERIENCE OF ALLOGENEIC HAEMOPOIETIC STEM CELL TRANSPLANT IN SINGAPORE
DURABLE LONG‐TERM REMISSION IN HIGH‐RISK RELAPSE REFRACTORY LYMPHOMA—20 YEARS’ EXPERIENCE OF ALLOGENEIC HAEMOPOIETIC STEM CELL TRANSPLANT IN SINGAPORE Open
Background: Allogeneic hematopoietic stem cell transplantation (AlloHSCT) is a curative option for those who have high risk relapsed/refractory lymphoma in the era of novel and cellular therapies including CAR-T cell. There is a paucity of…
View article: ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): RESULTS FROM A PRESPECIFIED ANALYSIS OF THE PIVOTAL PHASE II STUDY ELM‐2
ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): RESULTS FROM A PRESPECIFIED ANALYSIS OF THE PIVOTAL PHASE II STUDY ELM‐2 Open
Introduction: Odronextamab is a CD20×CD3 bispecific antibody (Ab). In ELM-1 (Ph1, NCT02290951), odronextamab demonstrated encouraging activity and a generally manageable safety profile in patients (pts) with heavily pretreated DLBCL (Banne…
View article: REAL WORLD EXPERIENCE OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA IN A MULTI‐ETHNIC ASIAN COHORT
REAL WORLD EXPERIENCE OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA IN A MULTI‐ETHNIC ASIAN COHORT Open
Introduction: Primary Central Nervous System Lymphoma (PCNSL) is a rare and intractable disease with a dismal prognosis. There is a paucity of data on Asian patients' outcome, we aimed to review the clinicopathologic characteristics and pr…
View article: ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) GRADE 1–3A: RESULTS FROM A PRESPECIFIED ANALYSIS OF THE PIVOTAL PHASE II STUDY ELM‐2
ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) GRADE 1–3A: RESULTS FROM A PRESPECIFIED ANALYSIS OF THE PIVOTAL PHASE II STUDY ELM‐2 Open
Introduction: Odronextamab is a CD20 × CD3 bispecific antibody (Ab). In the Phase 1 ELM-1 study (NCT02290951), odronextamab demonstrated potent antitumor activity and a generally manageable safety profile in patients (pts) with heavily pre…
View article: Supplementary Data from Phase I Trial of Expanded, Activated Autologous NK-cell Infusions with Trastuzumab in Patients with HER2-positive Cancers
Supplementary Data from Phase I Trial of Expanded, Activated Autologous NK-cell Infusions with Trastuzumab in Patients with HER2-positive Cancers Open
Supplementary Materials, Figures
View article: Data from Phase I Trial of Expanded, Activated Autologous NK-cell Infusions with Trastuzumab in Patients with HER2-positive Cancers
Data from Phase I Trial of Expanded, Activated Autologous NK-cell Infusions with Trastuzumab in Patients with HER2-positive Cancers Open
Purpose:Natural killer (NK) cells exert antibody-dependent cell cytotoxicity (ADCC). We infused expanded, activated autologous NK cells to potentiate trastuzumab-mediated ADCC in patients with HER2-positive malignancies.Patients and Method…
View article: Supplementary Data from Phase I Trial of Expanded, Activated Autologous NK-cell Infusions with Trastuzumab in Patients with HER2-positive Cancers
Supplementary Data from Phase I Trial of Expanded, Activated Autologous NK-cell Infusions with Trastuzumab in Patients with HER2-positive Cancers Open
Supplementary Materials, Figures
View article: Data from Phase I Trial of Expanded, Activated Autologous NK-cell Infusions with Trastuzumab in Patients with HER2-positive Cancers
Data from Phase I Trial of Expanded, Activated Autologous NK-cell Infusions with Trastuzumab in Patients with HER2-positive Cancers Open
Purpose:Natural killer (NK) cells exert antibody-dependent cell cytotoxicity (ADCC). We infused expanded, activated autologous NK cells to potentiate trastuzumab-mediated ADCC in patients with HER2-positive malignancies.Patients and Method…
View article: Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial
Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial Open
PURPOSE Epcoritamab is a subcutaneously administered CD3xCD20 T-cell–engaging, bispecific antibody that activates T cells, directing them to kill malignant CD20 + B cells. Single-agent epcoritamab previously demonstrated potent antitumor a…
View article: A genomic‐augmented multivariate prognostic model for the survival of natural‐killer/T‐cell lymphoma patients from an international cohort
A genomic‐augmented multivariate prognostic model for the survival of natural‐killer/T‐cell lymphoma patients from an international cohort Open
With lowering costs of sequencing and genetic profiling techniques, genetic drivers can now be detected readily in tumors but current prognostic models for Natural‐killer/T cell lymphoma (NKTCL) have yet to fully leverage on them for progn…
View article: Treatment outcomes of T and natural‐killer/T‐cell lymphoma with ifosfamide, carboplatin and etoposide chemotherapy
Treatment outcomes of T and natural‐killer/T‐cell lymphoma with ifosfamide, carboplatin and etoposide chemotherapy Open
Background Contemporary data of peripheral T‐cell lymphoma (PTCL) and natural‐killer/T‐cell lymphoma (NKTL) patients treated with ifosfamide, carboplatin and etoposide (ICE) are limited. Aims We performed a retrospective analysis to estima…
View article: Enhanced BNT162b2 vaccine-induced cellular immunity in anti-CD19 CAR T cell–treated patients
Enhanced BNT162b2 vaccine-induced cellular immunity in anti-CD19 CAR T cell–treated patients Open
Patients receiving CD19 CAR T-cell therapy for relapsed/refractory lymphoma experience prolonged and profound B-cell aplasia and hypogammaglobulinemia, placing them at a higher risk for severe COVID-19. Independently, Oh et al and Atanacko…
View article: Determinants of response to daratumumab in Epstein-Barr virus-positive natural killer and T-cell lymphoma
Determinants of response to daratumumab in Epstein-Barr virus-positive natural killer and T-cell lymphoma Open
Background The potential therapeutic efficacy of daratumumab in natural killer T-cell lymphoma (NKTL) was highlighted when its off-label usage produced sustained remission in a patient with highly refractory disease. This is corroborated r…
View article: Rapid production of clinical‐grade SARS‐CoV‐2 specific T cells
Rapid production of clinical‐grade SARS‐CoV‐2 specific T cells Open
High frequencies of rapid antigen-reactive T cells were found in convalescent donors, regardless of severity of COVID-19. The feasibility of clinical-grade production of SARS-CoV-2-specific T cells overnight for therapeutics and diagnostic…
View article: SUCCESSFUL MANUFACTURING OF CLINICAL-GRADE SARS-CoV-2 SPECIFIC T CELLS FOR ADOPTIVE CELL THERAPY
SUCCESSFUL MANUFACTURING OF CLINICAL-GRADE SARS-CoV-2 SPECIFIC T CELLS FOR ADOPTIVE CELL THERAPY Open
SUMMARY Background Adoptive therapy with SARS-CoV-2 specific T cells for COVID-19 has not been reported. The feasibility of rapid clinical-grade manufacturing of virus-specific T cells from convalescent donors has not been demonstrated for…
View article: A multi-institutional analysis of diffuse large B-cell lymphoma (DLBCL) treated with consolidative radiotherapy and the impact of cell-of-origin on outcomes
A multi-institutional analysis of diffuse large B-cell lymphoma (DLBCL) treated with consolidative radiotherapy and the impact of cell-of-origin on outcomes Open
Background Patients with diffuse large B-cell lymphoma (DLBCL) with bulky disease and/or those who fail to achieve complete response benefit from the addition of radiotherapy (RT). We aim to review the outcome, as well as determine the imp…